These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7499447)

  • 101. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
    Atzpodien J; Poliwoda H; Kirchner H
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
    Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
    Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.
    Palmer PA; Vinke J; Philip T; Negrier S; Atzpodien J; Kirchner H; Oskam R; Franks CR
    Ann Oncol; 1992 Jun; 3(6):475-80. PubMed ID: 1498066
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
    Oliver RT
    Br J Cancer; 1998 Apr; 77(8):1318-20. PubMed ID: 9579839
    [No Abstract]   [Full Text] [Related]  

  • 108. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 109. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
    Padrik P
    Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
    Bukowski RM
    Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
    [TBL] [Abstract][Full Text] [Related]  

  • 112. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Bukowski RM
    Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
    [TBL] [Abstract][Full Text] [Related]  

  • 115. [Cytokine therapy of metastatic renal cell carcinoma].
    Otto T; Goepel M; Luboldt HJ; Rübben H
    Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 118. A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
    Zustovich F; Cartei G; Dal Bianco M; De Zorzi L; Ceravolo R; Zovato S; Salmaso F; Binato S; Artioli G; Cingarlini S; Pastorelli D
    Ann Oncol; 2006 May; 17 Suppl 5():v133-6. PubMed ID: 16807442
    [No Abstract]   [Full Text] [Related]  

  • 119. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.
    Canobbio L; Rubagotti A; Miglietta L; Cannata D; Curotto A; Amoroso D; Boccardo F
    J Cancer Res Clin Oncol; 1995; 121(12):753-6. PubMed ID: 7499447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 6.